Lucid Genetics, Corp.

Lucid Genetics is a clear way of understanding your body's genetic code and how it relates to your current and future health. Now, no matter where you are, you can meet with one of our boarded physicians to discuss a disease that has been in your family, an undiagnosed rare disease or your own history with a specific condition. From this live one on one meeting we can decide what genetic tests would be right for you.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

DYADIC ANNOUNCES A NIIMBL CORONAVIRUS GRANT UNDER THE WHITE HOUSE’S AMERICAN RESCUE PLAN

Dyadic International, Inc. | December 23, 2021

news image

Dyadic International, Inc. a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve access to biologic vaccines and drugs at flexible commercial scales, announced it is the recipient of one of thirty-two project grants awarded by the National Institute for Innovation in Manufacturing Biopharmaceuticals funded through the White House’s American Rescue ...

Read More

INOVIO REPORTS FDA PARTIAL CLINICAL HOLD FOR PLANNED PHASE 2 / 3 TRIAL OF COVID-19 VACCINE CANDIDATE INO-4800

INOVIO | September 28, 2020

news image

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced that the U.S. Food and Drug Administration (FDA) has notified the company it has additional questions about the company's planned Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA® 2000 delivery device to be used in the trial. Until the FDA's questions have been satisfac...

Read More

DECK 7 INTERVIEWS SANGRAM VAJRE, CO-FOUNDER & CHIEF EVANGELIST AT TERMINUS

PR.com | January 13, 2020

news image

DECK 7 is proud to present an exciting interview with the Co-Founder & Chief Evangelist at Terminus, Sangram Vajre. He is an author, keynote speaker, 3x CMO, host of the daily #FlipMyFunnel podcast, entrepreneur and category maker. Sangram has been a driving force behind the success of Terminus and building the ABM subcategory of marketing technology. Before co-founding Terminus, Sangram was Head of Marketing at Pardot through its acquisition by ExactTarget and then Salesforce. A contributin...

Read More

MEDICAL

TRIALSPARK, COMMITTS TO IMPROVE SPEED, QUALITY, AND INNOVATION OF CLINICAL TRIALS, ANNOUNCES COLLABORATION WITH ADITUM BIO

TrialSpark | December 21, 2020

news image

TrialSpark, a tech-enabled drug development accomplice focused on improving the speed, quality, and innovation of clinical trials, officially announces a collaboration with Aditum Bio, a San Francisco-based venture endeavor firm engaged with respect to getting and creating biotechnology resources that will benefit patients. Anteris Bio in-licensed ANT-401 from vTv Therapeutics, to be studied in CKD and across multiple etiologies of renal diseases. As Aditum Bio's drug developm...

Read More
news image

CELL AND GENE THERAPY

DYADIC ANNOUNCES A NIIMBL CORONAVIRUS GRANT UNDER THE WHITE HOUSE’S AMERICAN RESCUE PLAN

Dyadic International, Inc. | December 23, 2021

Dyadic International, Inc. a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve access to biologic vaccines and drugs at flexible commercial scales, announced it is the recipient of one of thirty-two project grants awarded by the National Institute for Innovation in Manufacturing Biopharmaceuticals funded through the White House’s American Rescue ...

Read More
news image

INOVIO REPORTS FDA PARTIAL CLINICAL HOLD FOR PLANNED PHASE 2 / 3 TRIAL OF COVID-19 VACCINE CANDIDATE INO-4800

INOVIO | September 28, 2020

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced that the U.S. Food and Drug Administration (FDA) has notified the company it has additional questions about the company's planned Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA® 2000 delivery device to be used in the trial. Until the FDA's questions have been satisfac...

Read More
news image

DECK 7 INTERVIEWS SANGRAM VAJRE, CO-FOUNDER & CHIEF EVANGELIST AT TERMINUS

PR.com | January 13, 2020

DECK 7 is proud to present an exciting interview with the Co-Founder & Chief Evangelist at Terminus, Sangram Vajre. He is an author, keynote speaker, 3x CMO, host of the daily #FlipMyFunnel podcast, entrepreneur and category maker. Sangram has been a driving force behind the success of Terminus and building the ABM subcategory of marketing technology. Before co-founding Terminus, Sangram was Head of Marketing at Pardot through its acquisition by ExactTarget and then Salesforce. A contributin...

Read More
news image

MEDICAL

TRIALSPARK, COMMITTS TO IMPROVE SPEED, QUALITY, AND INNOVATION OF CLINICAL TRIALS, ANNOUNCES COLLABORATION WITH ADITUM BIO

TrialSpark | December 21, 2020

TrialSpark, a tech-enabled drug development accomplice focused on improving the speed, quality, and innovation of clinical trials, officially announces a collaboration with Aditum Bio, a San Francisco-based venture endeavor firm engaged with respect to getting and creating biotechnology resources that will benefit patients. Anteris Bio in-licensed ANT-401 from vTv Therapeutics, to be studied in CKD and across multiple etiologies of renal diseases. As Aditum Bio's drug developm...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us